Myocardial XXXX delivery/consumption during cardiopulmonary resuscitation: a comparison of @entity1425 and @entity2647 .

@entity1707 @entity296 @entity1425 @entity26 @entity2647 @entity2224
Our study compared the effect of high-dose @entity1425 with the pure alpha-agonist @entity2647 on regional @entity296 ( @entity296 ), myocardial @entity26 delivery (MDO2), myocardial @entity26 consumption (MVO2), and defibrillation rates during CPR. Fifteen @entity1707 weighing more than 15 kg were instrumented for measurement of regional @entity296 using radiolabeled tracer microspheres. Measurements of regional @entity296 , MDO2, and MVO2 were made during normal sinus rhythm. @entity2224 was induced and persisted for ten minutes. CPR was begun using a pneumatic compression device. Regional @entity296 , MDO2, and MVO2 were measured during CPR. Following three minutes of CPR, animals (N = 15) were allocated to one of three groups (n = 5): Group 1, @entity1425 0.2 mg/kg; Group 2, @entity2647 0.1 mg/kg; or Group 3, @entity2647 1.0 mg/kg. Measurements of regional @entity296 , MDO2, and MVO2 were repeated after drug administration. Extraction ratios, defined as MVO2/MDO2, were calculated during normal sinus rhythm, CPR, and after drug administration. Defibrillation was attempted 3 1/2 minutes after drug administration. There was no significant difference in @entity296 , MDO2, MVO2, and extraction ratio during normal sinus rhythm and CPR for any of the groups. Total @entity296 following drug administration was 67.2 +/- 49.4 mL/min/100 g for the group receiving @entity1425 0.2 mg/kg; 7.0 +/- 7.1 mL/min/100 g for the group receiving @entity2647 0.1 mg/kg; and 36.7 +/- 21.1 mL/min/100 g for the group receiving @entity2647 1.0 mg/kg.(ABSTRACT TRUNCATED AT 250 WORDS)
